Exicure, Inc. is an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. The Company, through GPCR Therapeutics USA Inc. (GPCR USA), is focused on developing and commercializing an intellectual property and patents related to G-Protein Coupled Receptors. GPCR USA is conducting a Phase II clinical trial for a blood cancer treatment involving GPC-100 (Burixafor). The Company is also exploring strategic alternatives to maximize stockholder value.
äŒæ¥ã³ãŒãXCUR
äŒç€ŸåExicure Inc
äžå Žæ¥May 09, 2018
æé«çµå¶è²¬ä»»è
ãCEOãYoo (Andy)
åŸæ¥å¡æ°7
蚌åžçš®é¡Ordinary Share
æ±ºç®ææ«May 09
æ¬ç€Ÿæåšå°2430 N. Halsted St.
éœåžCHICAGO
蚌åžååŒæNASDAQ OMX - NASDAQ BASIC
åœUnited States of America
éµäŸ¿çªå·60614
é»è©±çªå·18476731707
ãŠã§ããµã€ãhttps://www.exicuretx.com/
äŒæ¥ã³ãŒãXCUR
äžå Žæ¥May 09, 2018
æé«çµå¶è²¬ä»»è
ãCEOãYoo (Andy)